Exploring the role of different drug transport routes in permeability screening

被引:107
作者
Matsson, P
Bergström, CAS
Nagahara, N
Tavelin, S
Norinder, U
Artursson, P
机构
[1] Uppsala Univ, Dept Pharm, Ctr Pharmaceut Informat, Uppsala Biomed Ctr, SE-75123 Uppsala, Sweden
[2] AstraZeneca Res & Dev, Dept Med Chem, SE-15185 Sodertalje, Sweden
关键词
D O I
10.1021/jm049711o
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The influence of different drug transport routes in intestinal drug permeability screening assays was studied. Three experimental models were compared: the small-intestine-like 2/4/A1 cell model, which has a leaky paracellular pathway, the Caco-2 cell model, which has a tighter paracellular pathway, and artificial hexadecane membranes (HDMs), which exclusively model the passive transcellular pathway. The models were investigated regarding their ability to divide passively and actively transported compounds into two permeability classes and to rank compounds according to human intestinal absorption. In silico permeability models based on two-dimensional (2D) and three-dimensional (3D) molecular descriptors were also developed and validated using external test sets. The cell-based models classified 80% of the acceptably absorbed compounds (FA greater than or equal to 30%) correctly, compared to 60% correct classifications using the HDM model. The best compound ranking was obtained with 2/4/A1 (r(s) = 0.74; r(s) = 0.95 after removing actively transported outliers). The in silico model based on 2/4/A1 permeability gave results of similar quality to those obtained when using experimental permeability, and it was also better than the experimental HDM model at compound ranking (r(s) = 0.85 and 0.47, respectively). We conclude that the paracellular transport pathway present in the cell models plays a significant role in models used for intestinal permeability screening and that 2/4/A1 in vitro and in silico models are promising alternatives for drug discovery permeability screening.
引用
收藏
页码:604 / 613
页数:10
相关论文
共 71 条
[1]   PASSIVE DIFFUSION OF WEAK ORGANIC ELECTROLYTES ACROSS CACO-2 CELL MONOLAYERS - UNCOUPLING THE CONTRIBUTIONS OF HYDRODYNAMIC, TRANSCELLULAR, AND PARACELLULAR BARRIERS [J].
ADSON, A ;
BURTON, PS ;
RAUB, TJ ;
BARSUHN, CL ;
AUDUS, KL ;
HO, NFH .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (10) :1197-1204
[2]   QUANTITATIVE APPROACHES TO DELINEATE PARACELLULAR DIFFUSION IN CULTURED EPITHELIAL-CELL MONOLAYERS [J].
ADSON, A ;
RAUB, TJ ;
BURTON, PS ;
BARSUHN, CL ;
HILGERS, AR ;
AUDUS, KL ;
HO, NFH .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1994, 83 (11) :1529-1536
[3]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[4]   Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond [J].
Artursson, P ;
Borchardt, RT .
PHARMACEUTICAL RESEARCH, 1997, 14 (12) :1655-1658
[5]   CORRELATION BETWEEN ORAL-DRUG ABSORPTION IN HUMANS AND APPARENT DRUG PERMEABILITY COEFFICIENTS IN HUMAN INTESTINAL EPITHELIAL (CACO-2) CELLS [J].
ARTURSSON, P ;
KARLSSON, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 175 (03) :880-885
[6]   Caco-2 monolayers in experimental and theoretical predictions of drug transport (Reprinted from Advanced Drug Delivery Reviews, vol 22, pg 67-84, 1996) [J].
Artursson, P ;
Palm, K ;
Luthman, K .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 46 (1-3) :27-43
[7]  
Avdeef A., 2003, ABSORPTION DRUG DEV, DOI [10.1002/047145026X, DOI 10.1002/047145026X]
[8]   Absorption classification of oral drugs based on molecular surface properties [J].
Bergström, CAS ;
Strafford, M ;
Lazorova, L ;
Avdeef, A ;
Luthman, K ;
Artursson, P .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (04) :558-570
[9]   Comparison of passive drug transport through Caco-2 cells and artificial membranes [J].
Camenisch, G ;
Folkers, G ;
vandeWaterbeemd, H .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 147 (01) :61-70
[10]  
Chiou WL, 2001, INT J CLIN PHARM TH, V39, P93